So in other words if they don't commercialise it by 31/10 then they still can but we can also provide MK to a competitor who may be looking to offer a similar test. $$$$
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
